Armistice Capital, LLC's Form 4 filing
Avalo Therapeutics, Inc.AVTX · filed Mar 14, 2022
- Accession no.
- 0000899243-22-010904
- Filed
- Mar 14, 2022, 5:38 PM ET
- Trade date
- Mar 10-14, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market purchases total $151.9K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Armistice Capital, LLCCIK 0001601086 | Director, 10% Owner |
| Armistice Capital Master Fund Ltd.CIK 0001633584 | Director, 10% Owner |
| Boyd StevenCIK 0001706140 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 10, 2022 | Common Stock | PPurchaseAcquired | +26,000 | $0.701 | +$18,226 | 47,376,000 | Indirect | |
| Mar 11, 2022 | Common Stock | PPurchaseAcquired | +100,000 | $0.6878 | +$68,780 | 47,476,000 | Indirect | |
| Mar 14, 2022 | Common Stock | PPurchaseAcquired | +100,000 | $0.6494 | +$64,940 | 47,576,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Each of the Master Fund and Armistice Capital may be deemed a director by deputization of the Issuer by virtue of the fact that Steven Boyd, a representative of the Master Fund and Armistice Capital, currently serves on the Issuer's board of directors.